Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs

Yao, Jing; Shi, Ya-Qin; Li, Zhuorong; Shao-hong, Jin

doi:10.1016/j.jchromb.2007.03.022

Cited by 65 publications

(35 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glibenclamide was used as internal standard. The run time for the assay was 10 min, and the retention time for the drug was 3.9±0.2 min and glipenclamide retention time was 7.9±0.3 min[1617]. …”

Section: Methodsmentioning

confidence: 99%

Microencapsulation approach for orally extended delivery of glipizide: In vitro and in vivo evaluation

Abdelbary¹,

Na²,

Hosny³

2012

Indian J Pharm Sci

View full text Add to dashboard Cite

Glipizide is an effective antidiabetic agent, however, it suffers from relatively short biological half-life. To solve this encumbrance, it is a prospective candidate for fabricating glipizide extended release microcapsules. Microencapsulation of glipizde with a coat of alginate alone or in combination with chitosan or carbomer 934P was prepared employing ionotropic gelation process. The prepared microcapsules were evaluated in vitro by microscopical examination, determination of the particle size, yield and microencapsulation efficiency. The filled capsules were assessed for content uniformity and drug release characteristics. Stability study of the optimised formulas was carried out at three different temperatures over 12 weeks. In vivo bioavailability study and hypoglycemic activity of C9 microcapsules were done on albino rabbits. All formulas achieved high yield, microencapsulation efficiency and extended t1/2. C9 and C19 microcapsules attained the most optimised results in all tests and complied with the dissolution requirements for extended release dosage forms. These two formulas were selected for stability studies. C9 exhibited longer shelf-life and hence was chosen for in vivo studies. C9 microcapsules showed an improvement in the drug bioavailability and significant hypoglycemic activity compared to immediate release tablets (Minidiab® 5 mg). The optimised microcapsule formulation developed was found to produce extended antidiabetic activity.

show abstract

Section: Methodsmentioning

confidence: 99%

Microencapsulation approach for orally extended delivery of glipizide: In vitro and in vivo evaluation

Abdelbary¹,

Na²,

Hosny³

2012

Indian J Pharm Sci

View full text Add to dashboard Cite

show abstract

“…An orifice ionotropic gelation process that has been extensively used to prepare large alginate beads was employed to fabricate the microcapsules. [15,16] Formulation of SA coated gliclazide microcapsules Alginate coated microcapsules of gliclazide were prepared by dispersing the drug (15 mg) into aqueous solutions of SA under constant stirring (500 rpm) at 25 ± 0.5° for 10 min. The microcapsules were formed by dropping the dispersion into gently agitated aqueous solutions of the counter ion 0.2 M CaCl 2 at a rate of 3 ml/min through a syringe with a needle of size no.…”

Section: Formulation Of Gliclazide Microcapsulesmentioning

confidence: 99%

“…Samples were filtered through Whatman filter membrane (0.45 µm), diluted appropriately and analyzed spectrophotometrically at 276 nm for the percent gliclazide released. [16] All experiments were done in triplicate. The obtained data were subsequently analyzed to determine the order of release.…”

Section: Release Studiesmentioning

confidence: 99%

Untitled

Saxena¹

2017

AJP

View full text Add to dashboard Cite

Aim: Microcapsules and transdermal patch: A parallel access for improved delivery of antidiabetic drug. Materials and Methods: Different formulations were formulated employing sodium alginate (SA) alone or in combination with various coating polymers. Alginate coated microcapsules of gliclazide were prepared by dispersing the drug (15 mg) into aqueous solutions of SA under constant stirring. Preparation of transdermal patches (TDP): Glibenclamide (GL)-loaded TDP formulations were prepared by solvent casting method with slight modification. Hydroxypropyl methylcellulose was dissolved in a mixture of acetone/isopropyl alcohol/ethanol (50:30:20) with continuous stirring in a closed system at 25°C. Evaluation of the prepared microcapsules: Microscopical examination and particle size measurement of gliclazide microcapsules were done using an optical microscope. The prepared microcapsules were mounted in few drops of distilled water and examined under an optical microscope. Evaluation of TDP: Several steps such as moisture intake, moisture uptake, and weight variation are used for evaluation method. Conclusion: From the comparative study, it was concluded that the transdermal system of GL produced better improvement compared to oral microcapsule administration.

show abstract

“…Its therapeutic blood glucose-normalizing action is dependent on the presence of circulating insulin. Various methods have been reported for the analysis of metformine alone or its combination with other drugs in different dosage forms is capillary electrophoresis [1,2], HPLC [3,4], Liquid chromatography-mass spectrometry (LCMS), [5], spectrophotometric [6], High performance thin layer chromatography (HPTLC) [7] and spectrofluorometric method [8].…”

Section: Introductionmentioning

confidence: 99%

“…It stimulates the secretion and enhances the utilization of insulin by appropriate tissues. Different methods have been reported for the analysis of Glibenclamide alone or its combination with other drugs is HPLC [19][20][21][22][23][24], voltametric [25], spectophotometry [25] and LCMS/ MS [26].…”

Section: Introductionmentioning

confidence: 99%

Method Development and Validation of Metformine, Pioglitazone and Glibenclamide in Tablet Dosage Form by using RP-HPLC

Tengli¹

2013

Biochem Anal Biochem

View full text Add to dashboard Cite

Reverse phase high performance liquid chromatographic method has developed for the simultaneous estimation of metformine, pioglitazone and glibenclamide in tablet dosage for using gliclazide as an internal standard. The separation was achieved at ambient temperature with low pressure gradient mode by using 5 µ size phenomenex luna CN (100R 250×4.60 (mm) column with mobile phase containing acetonitrile, water and buffer (0.5% potassium dihydrogen phosphate) pH 2.5 adjusted with orthophosphoic acid in the ratio of 60:20:20. The flow rate was 1 mL min -1 and eluent was monitored at 230 nm by using UV detector. The selected chromatographic conditions effectively separated Metformine, pioglitazone and Glibenclamide with the retention time of 2.2, 2.8 and 5.8 min respectively. The linearity range for metformine, pioglitazone and glibenclamide is found in the range of 50-300 µg mL -1 , 1.5-9.0 µg mL -1 and 0.5-3.0 µg mL -1 respectively. The developed method was found to be accurate, simple, specific and reproducible. It can also be used for routine quality control analysis of these antidiabetic drugs in combinational dosage forms.

show abstract

Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs

Cited by 65 publications

References 6 publications

Microencapsulation approach for orally extended delivery of glipizide: In vitro and in vivo evaluation

Microencapsulation approach for orally extended delivery of glipizide: In vitro and in vivo evaluation

Untitled

Method Development and Validation of Metformine, Pioglitazone and Glibenclamide in Tablet Dosage Form by using RP-HPLC

Contact Info

Product

Resources

About